Literature DB >> 10959770

The chemokine/chemokine-receptor family: potential and progress for therapeutic intervention.

M A Cascieri1, M S Springer.   

Abstract

The chemokines are a large superfamily of chemotactic cytokines that are utilized to direct the trafficking and migration of leukocytes within the immune system. The chemokines mediate their activity through a large family of G-protein-coupled receptors, and thus are highly tractable as therapeutic targets. Exciting advances have been made in the field within the past year, not the least of which is the disclosure of potent antagonists of several chemokine receptors. Several CCR5 antagonists have demonstrated potent antiviral activity and may represent novel therapeutic agents for the treatment of AIDS. In addition, new biological insights have been gained from the demonstration that the targeting of cells to inflammatory sites is tissue specific, such that different chemokine/chemokine-receptor pairs are utilized in recruitment of T-lymphocytes to the skin and to the intestine. Also, utilization of neutralizing antibodies to the CXCR3 ligand Mig in murine allograft transplantation models has demonstrated the importance of CXCR3 in orchestrating T-cell-mediated tissue rejection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10959770     DOI: 10.1016/s1367-5931(00)00113-7

Source DB:  PubMed          Journal:  Curr Opin Chem Biol        ISSN: 1367-5931            Impact factor:   8.822


  20 in total

Review 1.  Design and implementation of high throughput screening assays.

Authors:  Ricardo Macarrón; Robert P Hertzberg
Journal:  Mol Biotechnol       Date:  2011-03       Impact factor: 2.695

Review 2.  Neutrophil recruitment to the lungs during bacterial pneumonia.

Authors:  Ann Craig; John Mai; Shanshan Cai; Samithamby Jeyaseelan
Journal:  Infect Immun       Date:  2008-11-17       Impact factor: 3.441

3.  The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; William A Kuziel; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

4.  Isolation of scFv fragments specific for monokine induced by interferon-gamma (MIG) using phage display.

Authors:  Edward Eteshola
Journal:  J Immunol Methods       Date:  2010-04-09       Impact factor: 2.303

Review 5.  Chemokines: new, key players in the pathobiology of pancreatic cancer.

Authors:  Karen E Hedin
Journal:  Int J Gastrointest Cancer       Date:  2002

Review 6.  The role of chemokines in leucocyte-stromal interactions in rheumatoid arthritis.

Authors:  Andrew Filer; Karim Raza; Mike Salmon; Christopher D Buckley
Journal:  Front Biosci       Date:  2008-01-01

Review 7.  Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field.

Authors:  M Rotondi; E Lazzeri; P Romagnani; M Serio
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

8.  The chemokine receptor antagonist, TAK-779, decreased experimental autoimmune encephalomyelitis by reducing inflammatory cell migration into the central nervous system, without affecting T cell function.

Authors:  Jia Ni; Yi-Na Zhu; Xiang-Gen Zhong; Yu Ding; Li-Fei Hou; Xian-Kun Tong; Wei Tang; Shiro Ono; Yi-Fu Yang; Jian-Ping Zuo
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

9.  The lupane-type triterpene 30-oxo-calenduladiol is a CCR5 antagonist with anti-HIV-1 and anti-chemotactic activities.

Authors:  Jonathan Barroso-González; Nabil El Jaber-Vazdekis; Laura García-Expósito; José-David Machado; Rafael Zárate; Angel G Ravelo; Ana Estévez-Braun; Agustín Valenzuela-Fernández
Journal:  J Biol Chem       Date:  2009-04-22       Impact factor: 5.157

Review 10.  Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease.

Authors:  Kengo Furuichi; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2008-12-16       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.